Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | MRD in CLL: utility from trials to individuals

John Seymour • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

John Seymour, MBBS, PhD, of the Peter MacCallum Cancer Center, Victoria, Australia, tells us his thoughts on measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL). Prof. Seymour discusses the utility of MRD for comparing the efficacy of different treatment regimens, and points to its emerging role in the management of individual patients. This interview was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from John Seymour

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:18
Efficacy of subsequent therapies for CLL patients treated in the MURANO trial
John Seymour • 8 Dec 2023
3:54
CLL advances: What will we see more of in 2021?
John Seymour • 7 Dec 2020
8:04
The MURANO study in CLL: 5 years on
John Seymour • 7 Dec 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals